These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23235919)

  • 41. Bulk compounding in Canadian hospitals--a survey.
    Taddio A; Wilson W
    Can J Hosp Pharm; 1990 Oct; 43(5):213-8, xxxii. PubMed ID: 10107923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On the shelf life of pharmaceutical products.
    Capen R; Christopher D; Forenzo P; Ireland C; Liu O; Lyapustina S; O'Neill J; Patterson N; Quinlan M; Sandell D; Schwenke J; Stroup W; Tougas T
    AAPS PharmSciTech; 2012 Sep; 13(3):911-8. PubMed ID: 22729779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug stability guidelines for a continuous infusion chemotherapy program.
    Vyas HM; Baptista RJ; Mitrano FP; Sesin GP
    Hosp Pharm; 1987 Jul; 22(7):685-7. PubMed ID: 10282686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined statistical analyses for long-term stability data with multiple storage conditions: a simulation study.
    Almalik O; Nijhuis MB; van den Heuvel ER
    J Biopharm Stat; 2014; 24(3):493-506. PubMed ID: 24697656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.
    Green DM; Jones AC; Brain KR
    J Clin Pharm Ther; 2012 Feb; 37(1):53-7. PubMed ID: 21501202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference.
    Bardin C; Astier A; Vulto A; Sewell G; Vigneron J; Trittler R; Daouphars M; Paul M; Trojniak M; Pinguet F;
    Ann Pharm Fr; 2011 Jul; 69(4):221-31. PubMed ID: 21840442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Draft guidelines on compounding of nonsterile products in pharmacies. American Society of Hospital Pharmacists.
    Am J Hosp Pharm; 1993 Jul; 50(7):1452-61. PubMed ID: 8362883
    [No Abstract]   [Full Text] [Related]  

  • 48. Updating formulations for compounded oral liquid medications in a university health system.
    Stumpf JL; Leja N; Ciarkowski SL; Salah S; Schaeffler KL
    Am J Health Syst Pharm; 2018 Sep; 75(18):1394-1398. PubMed ID: 30006436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey.
    Kairuz T; Chhim S; Hasan F; Kumar K; Lal A; Patel R; Singh R; Dogra M; Garg S
    N Z Med J; 2007 Mar; 120(1251):U2466. PubMed ID: 17384694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulatory requirements for veterinary vaccine stability in the European Community.
    Fawthrop D
    Dev Biol Stand; 1996; 87():319-27. PubMed ID: 8854032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Shelf life determination based on equivalence assessment.
    Tsong Y; Chen WJ; Lin TY; Chen CW
    J Biopharm Stat; 2003 Aug; 13(3):431-49. PubMed ID: 12921392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Premixed intravenous admixtures: a critical challenge for hospital pharmacy.
    Loeb AJ; Fishman DA; Kochis TR
    Am J Hosp Pharm; 1983 Jun; 40(6):1041-3. PubMed ID: 6869392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'.
    Kaestner S; Sewell G
    J Oncol Pharm Pract; 2007 Jun; 13(2):119-26. PubMed ID: 17873112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shelf lives of aseptically prepared medicines--stability of netilmicin injection in polypropylene syringes.
    Rigge DC; Jones MF
    J Pharm Biomed Anal; 2004 Sep; 35(5):1251-6. PubMed ID: 15336369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating Shelf Life Through Tolerance Intervals.
    Schwenke J; Quinlan M; Stroup W; Forenzo P
    AAPS PharmSciTech; 2020 Oct; 21(8):290. PubMed ID: 33079300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association.
    Di Pasqua AJ; Kerwood DJ; Shi Y; Goodisman J; Dabrowiak JC
    Dalton Trans; 2011 May; 40(18):4821-5. PubMed ID: 21461444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advice of manufacturers about effects of temperature on biologicals.
    Miller LG; Loomis JH
    Am J Hosp Pharm; 1985 Apr; 42(4):843-8. PubMed ID: 4014237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determining shelf life by comparing degradations at elevated temperatures.
    Magari RT; Munoz-Antoni I; Baker J; Flagler DJ
    J Clin Lab Anal; 2004; 18(3):159-64. PubMed ID: 15103679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.